New Lumigan Eye Drop Formulation for Glaucoma From Allergan Approved by FDA

September 1, 2010

Allergan has announced that the FDA has approved has approved LUMIGAN(R) (bimatoprost ophthalmic solution) 0.01% as a first-line therapy for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.  LUMIGAN(R) 0.01% is an optimized reformulation of LUMIGAN(R) (bimatoprost ophthalmic solution) 0.03%.

The approval followed a study showing that in patients with open-angle glaucoma or ocular hypertension with an average baseline of 23.5 mm Hg, LUMIGAN(R) 0.01% lowered IOP up to 7 mm Hg from baseline, with only one-third the drug exposure of LUMIGAN(R) 0.03%.

Read the full release issued by Allergan.



You might also enjoy...


Jump down to form below to submit your own comments

Trackback URL

Have insights to contribute? Please submit your comment below